We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » DEA Places Sage’s Postpartum Depression Drug in Schedule IV
DEA Places Sage’s Postpartum Depression Drug in Schedule IV
The Drug Enforcement Administration has placed Sage Therapeutics’ recently-approved postpartum depression drug Zulresso (brexanolone) in Schedule IV of its controlled substances list.